India, Aug. 14 -- Skye Bioscience, Inc. (SKYE), a biotechnology company, and privately held Redx Pharma announced a definitive transaction agreement to combine the companies and form Fibrx Therapeutics, a fibrosis-focused company expected to trade on the Nasdaq.
Transaction & Financing:
The transaction is expected to close in the fourth quarter of 2026, subject to shareholder and regulatory approvals. The combined company will be led by Redx's management team, with Lisa Anson serving as CEO and Peter Collum as CFO.
The companies also announced approximately $125 million in aggregate financing, including a $68 million Private Investment in Public Equity or PIPE financing, a $36 million Redx Series A financing and a $22 million committed e...